Table II.

Number of patients with proven myelodysplastic syndrome (MDS) who could be diagnosed by Ogata mini-panel, aberrancies of antigen expression and abnormal expression pattern and their combination

MDS subtype	Ogata mini-panel (A) score ≥2 (%)	Pattern analysis (B) score ≥3 (%)	Combining A+B and flow score ≥3 (%)
RCMD	4/8 (50)	7/8 (87.5)	8/8 (100)
RAEB-1	4/4 (100)	4/4 (100)	4/4 (100)
RAEB-2	8/9 (89)	9/9 (100)	9/9 (100)
MDS-U	1/1 (100)	1/1 (100)	1/1 (100)
5q-syndrome	2/2 (100)	1/2 (50)	2/2 (100)
Hypoplastic MDS	2/2 (100)	2/2 (100)	2/2 (100)
Total	21/26 (80.7)	24/26 (92.3)	26/26 (100)

RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anaemia with excess blasts-1; RAEB-2, refractory anaemia with excess blasts-2; MDS-U, MDS-unclassifiable